Tibolone vs Estradiol: What the Trials Show—and What U.S. Women Can Actually Use

The HRT Index Editorial TeamIndependent women's health research

Published:August 28, 2026Last reviewed:August 28, 2026

Editorial research — not medically reviewed by a clinician. Why this label

Last updated: August 28, 2026 · Last verified: August 28, 2026 · By The HRT Index Editorial Team. Educational research, not medical advice, and not reviewed by a clinician. See our medical review policy. Full disclosure.

Choose the care path, not just the molecule

The right alternative depends on your symptoms, menopause stage, uterus status, route preference, risk history, insurance, and state. Match those details before you book a U.S. menopause visit.

Find My HRT Path

Educational research, not medical advice. This page has not been reviewed by a clinician.

Tibolone vs estradiol is not a clean winner. Combined estrogen-plus-progestogen therapy is modestly more effective for hot flashes, while tibolone causes less unscheduled bleeding. Tibolone has no FDA-approved U.S. product, so U.S. women usually need an estradiol-based or other FDA-approved alternative. Country, menopause stage, uterus status, route, and risk history change the answer.

That is the short answer. Here is the part almost nobody tells you: “not approved in the U.S.” does not mean “banned as dangerous.” Organon received a Not Approvable Letter in June 2006 and announced that it would withdraw the application. Health Canada approved Tibella in 2019 after first issuing a Notice of Non-compliance. We can document those decisions. We cannot turn the timing into a public FDA explanation that does not exist.

We will show you the head-to-head numbers first, because that is what you came for. Then we will answer the question underneath the question: if tibolone is unavailable or wrong for your situation, what gives you the thing you actually wanted from it?

Best for / not for you

Tibolone may be worth discussing with a licensed clinician if you:

Live in a country where a tibolone product is currently licensed and marketed, such as Canada, the United Kingdom, or Australia
Are at least 12 months past your last natural menstrual bleed; the current UK and Canadian product information makes this a treatment-stage rule
Are younger than about 60 and have been screened for stroke, clot, breast, uterine, and other relevant risks
Strongly prefer one oral tablet and understand that tibolone has no patch, gel, spray, or vaginal form
Are struggling with unscheduled bleeding on combined HRT and want to compare the tradeoff rather than simply quitting

Tibolone is not your answer if you:

Live in the United States and want an FDA-approved product—there is none
Are still having natural periods, even irregular ones, or are less than 12 months from your last natural bleed
Have known, past, or suspected breast cancer; tibolone increased recurrence in a randomized trial of survivors
Have a history of stroke, transient ischemic attack, heart attack, angina, venous thromboembolism, or another label contraindication
Are older than about 60 without a careful stroke-risk discussion; the UK regulator says the balance begins to turn against tibolone at that age
Want a non-oral route
Mainly have vaginal dryness, urinary symptoms, or painful sex without hot flashes; a local treatment may fit that problem better than a whole-body drug

The 60-second version

Your question	The bottom line
Are tibolone and estradiol the same drug?	No. Tibolone is a synthetic steroid that is rapidly converted into three active metabolites. Estradiol is the estrogen molecule used in multiple systemic and local products.
Which controls hot flashes better?	Combined estrogen-progestogen therapy, modestly, in the pooled comparison. Tibolone still works substantially better than placebo.
Which causes less unscheduled bleeding?	Tibolone. In one randomized head-to-head trial, 16% of women on tibolone reported bleeding or spotting in weeks 1–12 versus 56% on a transdermal estradiol/norethisterone patch.
Which is better for libido?	Neither clearly won. In the main randomized head-to-head trial, satisfying sexual events rose from three to four per 28 days in both groups.
Do you add a separate progestogen?	The Livial label says no separate progestogen should be added. With systemic estradiol and an intact uterus, an endometrial-protection strategy is normally required. The endometrial section below is why those two statements are not interchangeable.
Can you get tibolone in the U.S.?	There is no FDA-approved product. We found no routine, transparent, verifiable U.S. pathway; personal importation discretion is case-specific, not a dependable right.
Is one safer?	Neither is “safer” as a blanket statement. Age, route, uterus status, breast history, clot and stroke risk, dose, and duration change the answer.

Before you go further: the answer depends on you

The right online HRT provider isn't the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care isn't the right starting point — before your first consult.

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

Why is “tibolone vs estradiol” an unfair comparison?

Bottom line: Tibolone is one oral drug with a standard licensed 2.5 mg daily regimen. “Estradiol” can mean a systemic patch, gel, spray, tablet, or ring—or a low-dose local vaginal product. Those routes are not interchangeable, and a study against one estradiol regimen cannot settle every other estradiol comparison.

Here is the damaging admission that changes how you should read the rest of this page:

“Tibolone vs estradiol” is partly a category error. Tibolone is one molecule and one route. Estradiol is a family of route-specific treatment paths. Oral and transdermal estrogen do not have the same clot-risk profile. Low-dose vaginal estrogen produces far less systemic exposure and is used for genitourinary symptoms, not for hot flashes. The Menopause Society separates systemic therapy for whole-body symptoms from low-dose local therapy for vaginal and urinary symptoms.

The direct tibolone studies also did not compare every route. The LISA trial used a transdermal estradiol/norethisterone patch. A small 2019 study used transdermal estradiol gel with dydrogesterone. Neither tells you what would happen against every patch dose, oral estradiol regimen, spray, gel, or vaginal product.

That is a real limitation, and we are not going to hide it behind confident language. What we can do is show each number beside the route, dose, and population that produced it. That final context column is the part most comparisons drop.

What is tibolone, and how is it different from estradiol?

Bottom line: Tibolone is a synthetic steroid taken orally and rapidly metabolized into three compounds: two with estrogen-like activity and one with progestogenic and androgenic activity. Estradiol products deliver estradiol itself. Tibolone is not estrogen, progesterone, and testosterone packaged together, and it is not a “bioidentical” hormone.

The current Livial product information describes three active metabolites: 3α-hydroxytibolone and 3β-hydroxytibolone, which have estrogenic activity, and the Δ4-isomer, which has progestogenic and androgenic activity. Tibolone levels in plasma are low because the drug is rapidly metabolized after oral administration.

That difference matters more than it sounds.

Estradiol is delivered as the hormone molecule itself. Tibolone gets much of its clinical activity through metabolites whose effects differ by tissue. That is why one tablet can affect hot flashes, bone, bleeding, breast tissue, and sexual-function measures without being equivalent to taking three separate hormones.

One thing you will read online that is wrong: tibolone is not “estrogen, progesterone, and testosterone in one pill.” Its metabolites act through estrogenic, progestogenic, and androgenic pathways. That is not the same as containing those hormones, and it does not make tibolone interchangeable with estradiol, progesterone, or testosterone products.

Verified brand examples include Livial in the United Kingdom and Australia and Tibella in Canada. Brand names and indications vary by country, so the national product label—not a forum post—governs the decision.

Tibolone vs estradiol: what are the 12 differences that actually matter?

Bottom line: Combined hormone therapy has the modest edge for hot flashes, tibolone has the clear early-bleeding advantage, and neither has a proven libido advantage on the outcome women directly experience. The biggest decision gates are country, menopause stage, estradiol route, uterus status, breast history, and arterial risk—not the marketing language around either drug.

This is the evidence asset the page is built around. The HRT Index assembled the same 12 decision factors across the licensed tibolone regimen, systemic estradiol paths, and low-dose local estradiol so you can see where a comparison is direct, indirect, or not meaningful.

Decision factor	Tibolone	Estradiol-based path	What the evidence supports	Population or route limit you cannot ignore
1. Drug identity	Synthetic steroid converted into estrogenic, progestogenic, and androgenic metabolites	Estradiol molecule delivered directly	They are not the same drug and are not dose-equivalent	“Estradiol” covers several routes and formulations
2. Route	Oral tablet only	Oral, patch, gel, spray, systemic ring, and local vaginal forms	Route changes convenience and risk	A tibolone result cannot be generalized to every estradiol route
3. Menopause stage	Current UK and Canadian labels place natural-menopause use more than 12 months after the last bleed	Systemic estradiol regimens may be used in perimenopause or postmenopause when clinically appropriate	Tibolone is not the flexible option for a woman still having natural periods	Surgical-menopause rules differ; country labels control
4. Hot flashes	Better than placebo; modestly less effective than combined HRT in Cochrane’s pooled comparison	Systemic estrogen is the most effective treatment class for vasomotor symptoms	Combined HRT has the average efficacy edge	Cochrane’s placebo and active-comparator percentages come from separate comparisons
5. Unscheduled bleeding	16% in weeks 1–12 in LISA; 12% in weeks 13–24	56% then 51% with the E2/NETA patch used in LISA	Tibolone’s clearest practical win	One specific patch comparator; not every combined regimen
6. Uterus / added progestogen	Livial label: do not add a separate progestogen	Systemic estradiol with an intact uterus normally needs endometrial protection	Tibolone is simpler, but simplicity is not proof of zero endometrial risk	Observational data and the current label still flag endometrial cancer
7. Sexual function	FSFI advantage only in per-protocol analysis	No significant intention-to-treat disadvantage	No clear winner	Satisfying sexual events rose from 3 to 4 in both LISA groups
8. Vaginal-only symptoms	Systemic drug	Low-dose vaginal estradiol targets local symptoms with much lower systemic exposure	Local estradiol is usually the more direct path when GSM is the whole problem	It is not designed to treat hot flashes
9. Bone	LIFT reduced vertebral and nonvertebral fractures	Systemic estradiol prevents bone loss while used	Both can protect bone	LIFT used 1.25 mg in women aged 60–85 with osteoporosis, not the standard 2.5 mg symptom regimen
10. Clot and stroke	Oral only; LIFT found a 2.19 stroke hazard in older osteoporotic women	Oral estrogen raises VTE risk; NICE says transdermal HRT does not increase VTE risk and that stroke risk is unlikely to increase with transdermal estrogen	Transdermal estradiol has the route advantage when clot risk drives the decision	Risk still requires individual screening; route does not erase all cardiovascular questions
11. Breast cancer	Contraindicated after breast cancer because LIBERATE increased recurrence; current UK labeling also reports an increased diagnosis risk with 2.5 mg use	Risk differs between estrogen-only and estrogen-progestogen regimens and by duration	Neither gets a blanket “safe” label	LIFT’s reduced breast-cancer signal came from a different, older osteoporotic population and should not be marketed as prevention
12. U.S. access	No FDA-approved U.S. product	Multiple FDA-approved estradiol and combination products	U.S. women need another regulated path	Compounding and import rules are more nuanced than “four closed doors,” but neither creates an ordinary approved prescription route

Read rows 6, 10, and 11 twice. Those are the rows that can turn an attractive convenience story into the wrong decision for a specific woman.

Which controls hot flashes better: tibolone or estradiol?

Bottom line: In Cochrane’s pooled evidence, tibolone was more effective than placebo but modestly less effective than combined hormone therapy for hot flashes and night sweats. The comparison does not prove that every estradiol formulation beats tibolone, but it does mean “equally effective” is too confident.

The Cochrane review included 46 randomized trials and 19,976 women. Its evidence search was current to October 2015.

The clean way to read its absolute examples is as two separate comparisons:

Tibolone versus placebo: if 67 of 100 women on placebo still had vasomotor symptoms, about 35 to 45 of 100 on tibolone would still have them.
Tibolone versus combined hormone therapy: if 7 of 100 women on combined HRT still had symptoms, about 8 to 14 of 100 on tibolone would still have them.

Do not combine those into one imaginary three-arm trial; doing so makes combined HRT look more dramatically superior than the review supports.

The fair conclusion is still clear: tibolone works; combined hormone therapy has a modest average edge. The Menopause Society describes systemic hormone therapy as the most effective treatment for bothersome hot flashes. The exact estradiol route and the need for endometrial protection still have to be chosen for the person in front of the prescriber.

What this means for you: if severe hot flashes and night sweats are the whole reason you are here, systemic estrogen-based therapy deserves the first comparison. Tibolone may still be reasonable where licensed, but the evidence does not justify treating it as the stronger vasomotor option.

One more honest note: we found no later large randomized tibolone-versus-estradiol trial that overturns Cochrane’s conclusion. The later direct comparison we found included only 57 women, was retrospective, let women choose their treatment, and had important baseline differences. It is a weak signal, not a new verdict.

Not sure whether hot flashes or something else should drive your choice?
The right starting point changes when the main problem is whole-body symptoms, vaginal symptoms, sleep, bleeding, or desire—and when you do or do not have a uterus. Answer a few questions before you book anything.
→ Get your personalized HRT path

Can you get tibolone in the United States?

Bottom line: There is no FDA-approved tibolone product in the United States. Importing an unapproved drug is generally illegal for U.S. residents, and FDA enforcement discretion is case-specific rather than a right. We found no routine, transparent, verifiable U.S. route—but the compounding law is too nuanced to support a blanket claim that every tibolone compound would automatically be unlawful.

This is the section most consumer pages skip, and it is where precision matters most.

A U.S. patient usually asks about three practical doors: an FDA-approved prescription, a compounded prescription, or personal importation. Here is what the public record supports.

Door 1: an FDA-approved tibolone product

Closed. In June 2006, Organon announced that the FDA had issued a Not Approvable Letter for tibolone as a treatment for menopausal symptoms. Organon said it intended to withdraw the application. As of August 2026, there is no FDA-approved tibolone product.

Important precision: tibolone was not recalled from the U.S. market, because it was never marketed here as an FDA-approved drug. “Not approved,” “banned,” “recalled,” and “withdrawn from the market” are not interchangeable.

Door 2: a patient-specific compound

This door is not routine, and the public evidence does not justify pretending it is simple.

Under section 503A, a compounding pharmacy may use a bulk drug substance when at least one of the relevant statutory conditions is met: an applicable USP or National Formulary monograph exists; the substance is a component of an FDA-approved drug; or the substance appears on the FDA’s 503A bulks list under the agency’s current framework.

We checked the FDA’s May 14, 2026 nominated-bulk-substances document. Tibolone does not appear in Category 1, 2, or 3. It is also not a component of an FDA-approved U.S. drug.

Here is the legal distinction that matters: absence from the nomination document does not by itself prove that every patient-specific use of tibolone bulk substance is unlawful, because an applicable USP/NF monograph is a separate statutory route. We could not verify current tibolone monograph status from a public authoritative USP source. We also did not independently establish a 503B outsourcing-facility pathway.

So we will not manufacture legal certainty. The practical conclusion is narrower and stronger: we found no ordinary, publicly verifiable U.S. compounding path for tibolone. A pharmacy offering it should be able to identify, in writing, the legal basis it relies on, the source of the bulk substance, the testing performed, and the fact that the finished product is not FDA-approved. A vague “we can compound anything your doctor orders” is not an answer.

Door 3: ordering tibolone from another country

For a U.S. resident, this is not a dependable workaround.

The FDA says that importing an unapproved prescription drug for personal use is illegal in most circumstances. Its personal importation policy describes circumstances in which the agency may consider enforcement discretion on a case-by-case basis. It is not a blanket permission slip, and no patient has a right to force a shipment through.

The policy is often reduced online to “four conditions, all met,” with the availability of U.S. menopause treatments treated as an automatic legal disqualification. That is too absolute. The actual FDA framework includes different considerations depending on the condition and circumstances, plus documentation and quantity limits. Only the FDA and border authorities decide what happens to a shipment.

The useful answer for a U.S. woman is still the same: do not build a treatment plan around an overseas package that may be detained, refused, delayed, or impossible to refill. The existence of FDA-approved systemic estradiol, combination hormone products, and nonhormone options makes a planned U.S. transition more reliable than trying to preserve tibolone through personal importation.

What we verified about U.S. access

What we checked	What the record supports	What it does not support
FDA-approved product	No FDA-approved tibolone product; Organon announced a Not Approvable Letter and withdrawal in June 2006	“Banned,” “recalled,” or “withdrawn from a U.S. market”
FDA 503A nomination document, updated May 14, 2026	Tibolone is absent from Categories 1, 2, and 3	A categorical conclusion about the separate USP/NF-monograph pathway
Personal importation policy	Importing unapproved drugs is generally illegal; discretion is case-specific and conditional	A guaranteed patient right to import tibolone
Routine U.S. access	No transparent, repeatable FDA-approved pathway was identified	Proof that no exceptional fact pattern could ever exist

That last row is deliberate. Precision is not weakness. It is what keeps every sentence tied to the source underneath it.

Why did the FDA say no when Canada said yes?

Bottom line: The FDA issued a Not Approvable Letter in June 2006 and the sponsor announced that it would withdraw the application. Health Canada approved Tibella in May 2019 after an initial Notice of Non-compliance and now restricts it to short-term vasomotor-symptom treatment more than one year after menopause in women with an intact uterus. The public record shows different regulatory outcomes, not a proven hidden reason.

Two North American regulators. One molecule. Different outcomes. Both on the public record.

Decision point	United States	Canada
Regulator outcome	Not Approvable Letter announced June 2006; sponsor said it would withdraw	Notice of Compliance granted May 10, 2019 after an earlier Notice of Non-compliance
Product today	No FDA-approved tibolone product	Tibella 2.5 mg; Canadian sales recorded from July 2020
Current indicated use	—	Short-term treatment of vasomotor symptoms more than one year after menopause
Uterus restriction	—	Current Canadian monograph says Tibella should be prescribed only to women with intact uteri
Review point	—	Reassess continuation after six months and continue only while benefit outweighs risk
Age warning	—	Give particular consideration to stroke risk in women over 60

The timing nobody should turn into a fact

In February 2006, the LIFT trial was stopped early because the tibolone group had more strokes.

In June 2006, Organon announced the FDA’s Not Approvable Letter.

We can give you the sequence. We cannot give you the cause. We found no public FDA review that explains the agency’s reasoning, and the sponsor withdrew instead of taking the application through a public approval process. Anyone who states flatly that “the FDA rejected tibolone because of LIFT” is connecting two public events with an inference.

It is a plausible inference. It is still an inference.

Health Canada later reached a different decision and approved a restricted product after an initial noncompliance decision. That does not prove the FDA was wrong. It proves that regulators can draw different benefit-risk lines from a mixed evidence base, in different years, for different labeled populations.

The third regulator gives the most useful age answer

The UK medicines regulator concluded that tibolone’s risk profile is broadly similar to conventional combined HRT in younger women. For women older than about 60, it said the risks begin to outweigh the benefits because of stroke.

That sentence is more useful than a hundred “Europe uses it, so it must be fine” comments. Country approval is not a personal safety screen.

Do you need progesterone or a progestogen with tibolone?

Bottom line: The Livial label says a separate progestogen should not be added. That is a dosing instruction, not proof that tibolone creates zero endometrial risk. The largest observational study found a higher rate of diagnosed endometrial cancer with tibolone than with estrogen-only HRT, while continuous combined estrogen-progestogen therapy had a lower rate on that one outcome.

This is the finding that reframes the entire comparison, and it is almost never shown beside the “one tablet” benefit.

The number-one practical reason many women want tibolone is convenience: one tablet, no second prescription, no separate progesterone schedule, and less bleeding than the combined patch used in LISA. That is completely reasonable. The current Livial label supports the instruction: a separate progestogen should not be added.

But “do not add a separate progestogen” and “your uterus has no remaining risk” are different claims.

The Million Women Study followed 716,738 postmenopausal women. Compared with women who had never used HRT, the reported relative risks for endometrial cancer among current users were:

Regimen in the Million Women Study	Relative risk of endometrial cancer
Tibolone	1.79 (95% CI 1.43–2.25)
Estrogen-only HRT	1.45
Sequential combined HRT	1.05
Continuous combined HRT	0.71

On this endometrial outcome, tibolone did not behave like the reassuring shortcut many women assume it is. A separate UK primary-care study found the same direction: women starting tibolone had an incidence-rate ratio of 1.83 for endometrial cancer compared with women starting combined sequential HRT.

The current UK product information now says observational studies have consistently shown an increased risk of having endometrial cancer diagnosed in women prescribed Livial in clinical practice. It also reports that the LIFT randomized trial found four endometrial cancers among 1,746 women assigned tibolone and none among 1,773 assigned placebo, equivalent in the label to about 0.8 additional case per 1,000 women for each year of use in that trial.

The honest limits, stated plainly: the Million Women Study and primary-care study were observational. Women prescribed tibolone may differ from women prescribed other regimens in ways statistical adjustment cannot erase. The LIFT endometrial numbers were small and came from older women with osteoporosis taking 1.25 mg, half the standard symptom dose. This is a signal with corroboration, not proof that every woman taking tibolone will have the same risk.

The damaging admission still stands:

If you have a uterus and tibolone appealed because it removes the separate progestogen, this is the paragraph you needed to read. The convenience is real. The protection may not be what you assumed.

Any bleeding or spotting that remains after six months, begins after that point, or continues after stopping tibolone should be reported and investigated under the current label. New postmenopausal bleeding also needs evaluation on estradiol-based therapy. Do not let a medication’s reputation for “less bleeding” talk you out of reporting the bleeding that does happen.

What if you want one product instead of two?

You do not have to leave the FDA-approved lane to reduce the number of products you manage in the United States.

Duavee combines conjugated estrogens with bazedoxifene for women with a uterus. Bazedoxifene is an estrogen agonist/antagonist rather than a progestogen. This is the closest practical U.S. concept to “one product without a separate progestogen,” but it does not contain estradiol and is not equivalent to tibolone.
Bijuva combines estradiol with micronized progesterone in one oral capsule.
Activella combines estradiol with norethindrone acetate in one oral tablet.
CombiPatch delivers estradiol and norethindrone acetate through one transdermal patch.

Three of those options still contain a progestogen. The gain is one FDA-approved combination product rather than a claim that progestogen exposure has disappeared. Which one fits depends on uterus status, route preference, contraindications, formulary, and what the prescriber is treating.

Which causes less bleeding: tibolone or estradiol HRT?

Bottom line: Tibolone causes less unscheduled bleeding than the combined estradiol/norethisterone patch used in the LISA trial, especially in the first six months. That is tibolone’s clearest head-to-head win. It does not make later or persistent bleeding safe to ignore.

We are not going to soften the number.

In the randomized LISA bleeding analysis:

During weeks 1–12, 16% of women taking tibolone reported bleeding or spotting, compared with 56% using the transdermal estradiol/norethisterone patch.
During weeks 13–24, the figures were 12% with tibolone and 51% with the patch.

Those are large practical differences. They help explain why a woman who is exhausted by pads, spotting, and uncertainty might prefer tibolone where it is licensed.

The current Livial label gives a second timeline:

Time on Livial 2.5 mg	Label-reported bleeding result
First 3 months	32.6% reported breakthrough bleeding and/or spotting
Months 11–12	11.6% reported breakthrough bleeding and/or spotting
At 12 months	88% were amenorrheic

That is also why “tibolone means no bleeding” is false. It means less, and generally less over time—not none.

Combined estradiol-progestogen regimens can settle too. The Activella label, for example, says irregular bleeding or spotting occurred in the first months and about 86% of women were amenorrheic after 12 months on its 1 mg/0.5 mg regimen. That does not erase LISA’s tibolone advantage; it stops a bad first three months from being mistaken for a permanent outcome.

What this means for you: if bleeding is driving you to stop treatment, do not disappear from care and do not switch yourself. Ask whether the cause is the regimen, the progestogen schedule, adherence, dose, another medication, or something that needs investigation. A different continuous regimen or route may solve the practical problem without importing a drug that is not approved where you live.

Does tibolone improve libido more than estradiol?

Bottom line: The best randomized head-to-head trial did not show a clear real-world libido advantage for tibolone. A sexual-function questionnaire favored tibolone only in the per-protocol analysis, while the stricter intention-to-treat analysis did not show a significant difference. Satisfying sexual events increased from three to four per 28 days in both groups.

This is the claim that brings many women to the comparison, so it deserves the full result rather than the headline.

The LISA trial randomized 403 naturally postmenopausal women with sexual dysfunction, average age 56, to tibolone 2.5 mg or a transdermal estradiol/norethisterone patch for 24 weeks.

The results, in the order that matters:

Satisfying sexual events: increased from three to four per 28 days in both groups. No significant difference.
Sexual distress: improved in both groups, with comparable change.
Female Sexual Function Index: tibolone scored higher in the per-protocol analysis, but not in the intention-to-treat analysis.

An intention-to-treat analysis keeps women in the group to which they were randomized, including those who did not finish exactly as planned. A per-protocol analysis keeps only those who followed the protocol closely. The second can answer a useful question, but it is more vulnerable to selection because the women who tolerate or benefit from a treatment are more likely to remain.

The trial was also manufacturer-sponsored, and the sponsor participated in design, data collection, analysis, interpretation, and writing. That does not invalidate the study. It does make the non-primary, per-protocol advantage the wrong foundation for a promise that tibolone “fixes libido better.”

When does this become a testosterone question?

Not every drop in desire is a testosterone problem. Pain with sex, vaginal dryness, sleep loss, hot flashes, depression, anxiety, relationship strain, medication effects, and other health conditions can all change sexual interest.

If low desire remains persistent, distressing, and unexplained after those factors are assessed, ask whether the pattern meets criteria for hypoactive sexual desire disorder. The international consensus statement says the only evidence-based indication for testosterone therapy in women is postmenopausal HSDD after a formal biopsychosocial assessment. The average benefit in trials was about one additional satisfying sexual event per month over placebo—real, but smaller than much marketing suggests.

There is no FDA-approved testosterone product for women in the United States. Testosterone is a Schedule III controlled substance and requires a legitimate prescription; nothing about menopause creates a route around that requirement. Compounded testosterone is not FDA-approved, and the consensus statement does not recommend compounded preparations when a product that can deliver an appropriate female dose is available.

What this means for you: if desire is the real reason you came here, do not choose tibolone because a metabolite is described as androgenic. First separate pain, arousal, desire, sleep, and relationship factors. Then take the right problem to a clinician instead of buying the strongest-sounding hormone story.

For a deeper evidence review, read Testosterone and low libido in women.

Which is safer for stroke, blood clots, breast cancer, and bone?

Bottom line: There is no honest one-word winner. Tibolone increased stroke in older women with osteoporosis and increased breast-cancer recurrence in survivors. Estradiol risk changes sharply by route and whether a progestogen is added. Transdermal estradiol has a practical clot-risk advantage over oral therapy, but it does not erase the need for an individual history.

Stroke and arterial risk

The LIFT trial randomized 4,538 women aged 60 to 85 with osteoporosis to tibolone 1.25 mg or placebo. After a median 34 months, stroke risk was more than doubled with tibolone: hazard ratio 2.19. The safety board stopped the trial in February 2006.

Now the detail that changes how you use the number: every participant was at least 60, all had osteoporosis, and the dose was 1.25 mg rather than the standard 2.5 mg symptom dose. The finding is directly relevant to older women and cannot be cleanly projected onto a healthy 52-year-old in either direction.

The UK regulator’s conclusion remains useful: tibolone’s risk profile is broadly similar to conventional combined HRT in younger women, but beyond about 60 the balance begins to turn against tibolone because baseline stroke risk rises with age.

A newer observational signal stops the conversation from ending with “LIFT only studied old women.” A 2024 Swedish target-trial emulation followed more than 900,000 women aged 50 to 58 and associated tibolone initiation with a higher composite cardiovascular risk than non-initiation, including higher ischemic-heart-disease risk. This was not a randomized trial, so confounding remains possible, but it is another reason not to treat age under 60 as immunity from arterial screening.

How estradiol route changes the decision

The most actionable route distinction comes from NICE:

Venous-thromboembolism risk is increased with oral HRT.
VTE risk is not increased with transdermal HRT.
Oral estrogen is associated with a small increase in stroke risk.
Stroke risk is unlikely to increase with transdermal estrogen in the evidence NICE reviewed.

That does not mean a patch is risk-free or right for everyone. It means tibolone cannot offer the same route choice because it is oral only. If clot risk is the reason you are comparing these drugs, transdermal estradiol deserves a separate line in the decision—not a generic “estradiol” column.

Breast cancer: do not use the LIFT signal as an advertisement

LIFT reported fewer new invasive breast cancers in the tibolone group, with a hazard ratio of 0.32. That is a real trial result. It is also the wrong result to turn into “tibolone prevents breast cancer.” Breast cancer was not the main reason the trial was designed, case numbers were small, the women were older and osteoporotic, and the trial used half the standard symptom dose.

Current UK product information now says a meta-analysis of epidemiologic studies, including the Million Women Study, found a significant increase in diagnosed breast-cancer risk with the 2.5 mg dose that became apparent within three years and rose with duration. The same label says the tibolone-associated increase is lower than the increase seen with combined estrogen-progestogen HRT—but lower is not zero.

In the LIBERATE trial, women treated for breast cancer within the previous five years had more recurrences with tibolone: 15.2% versus 10.7%, hazard ratio 1.40. The trial stopped early.

So the breast-cancer answer is not “protective in healthy women, harmful in survivors.” It is:

After breast cancer: tibolone is contraindicated. Systemic estrogen is generally avoided and any exception belongs with the oncology team.
Without breast cancer: risk depends on regimen, duration, baseline risk, and the evidence set used. Tibolone does not earn a cancer-prevention claim.

Bone

Both tibolone and systemic estrogen can protect bone while they are used. In LIFT, tibolone reduced vertebral fractures by 45% and nonvertebral fractures by 26% in older women with osteoporosis.

That is meaningful. It still may not decide a symptom-treatment choice. If fracture prevention is the primary problem, compare dedicated osteoporosis therapies as well as hormone therapy rather than assuming a menopause drug must carry the entire job.

Does tibolone cause weight gain or other side effects?

Bottom line: Weight increase appears as a common adverse reaction in the current Livial information. One small nonrandomized comparison found BMI rose with tibolone and fell slightly with transdermal estradiol, but its design is too weak to declare estradiol the weight-loss option. Track your own baseline and trend instead of treating either drug as a weight strategy.

The 2019 Korean comparison included 26 women choosing tibolone and 31 choosing transdermal estradiol gel plus dydrogesterone. The groups differed at baseline, treatment was not randomized, and the study was retrospective. It found a more favorable weight and BMI change in the transdermal group, but the result is a signal—not a clean causal answer.

The current Livial label lists common adverse effects that include lower abdominal pain, abnormal hair growth, vaginal discharge, endometrial-wall thickening, postmenopausal hemorrhage, breast tenderness, genital itching or irritation, pelvic pain, and weight increase. Less common or postmarketing effects include acne, edema, headache, migraine, dizziness, rash, depression, muscle or joint symptoms, and liver-test changes.

No list predicts what one woman will experience. It tells you what belongs in the baseline and follow-up conversation.

Six tibolone claims, checked against the record

Claim you will see	What the evidence actually says	What to do with it
“Tibolone does not stimulate the endometrium.”	Current labeling says observational studies consistently show increased diagnosed endometrial cancer and reports endometrial thickening	Report qualifying bleeding; do not treat “no added progestogen” as “no uterine follow-up”
“Tibolone does not cause weight gain.”	Weight increase is a listed common adverse reaction; one small weak study favored transdermal estradiol on BMI change	Record a baseline and reassess rather than believing either slogan
“Tibolone is better for libido.”	LISA found no intention-to-treat difference and identical satisfying-event change	Separate desire from pain, sleep, and GSM before choosing a hormone
“Tibolone is just as effective as HRT for hot flashes.”	Cochrane found it more effective than placebo but modestly less effective than combined HRT	Treat “equivalent” as too strong
“The FDA rejected it because of the stroke trial.”	The timing fits; no public FDA rationale proves the cause	State the sequence, not the speculation
“Tibolone is safer than estradiol.”	Risk shifts by age, route, uterus, breast history, and duration	Compare the actual regimen and person, not two drug names in isolation

A simple three-month log—symptoms, bleeding, weight, blood pressure if your clinician asks for it, and side effects—will tell your prescriber more than a generic “tibolone made me gain weight” thread ever can.

What can U.S. women use instead of tibolone?

Bottom line: Most women do not want tibolone as a molecule; they want one benefit they associate with it—one product, less bleeding, better sexual function, bone protection, or a way to avoid oral estrogen. Matching that friction point to an FDA-approved path is more useful than searching for a direct U.S. equivalent that does not exist.

Find the row that sounds like the reason you are still reading.

What you actually want	Why tibolone appealed	FDA-approved U.S. path to discuss	The honest catch
One product without a separate progestogen	Simplicity	Duavee: conjugated estrogens plus bazedoxifene for women with a uterus	Not estradiol, not tibolone, and not equivalent; it has its own contraindications and label
One product containing estradiol plus endometrial protection	One prescription to manage	Bijuva, Activella, or CombiPatch	They still expose you to a progestogen; the advantage is packaging and route, not removal of the hormone
Less unscheduled bleeding	The daily practical burden	Ask about continuous combined regimens, route, dose, and progestogen choice	Tibolone genuinely caused less early bleeding than the LISA patch; another regimen cannot promise the same number
Strong hot-flash control	Symptom relief	Systemic estrogen-based therapy, with endometrial protection when needed	The right route depends on clot, stroke, migraine, liver, gallbladder, and other history
Avoiding oral estrogen or reducing VTE concern	A “gentler” route	Transdermal estradiol patch, gel, or spray	Transdermal route improves the VTE comparison; it does not make all risk disappear
Help with low desire	Tibolone’s androgenic metabolite	Treat GSM or pain first; assess persistent distressing low desire for HSDD	No FDA-approved testosterone product exists for women; testosterone remains prescription-only and controlled
Bone protection	LIFT fracture data	Systemic estrogen when otherwise appropriate, plus a full osteoporosis assessment	If fracture prevention is the main goal, nonhormone osteoporosis drugs may be more targeted
Vaginal dryness, urinary symptoms, or painful sex only	Tibolone can affect urogenital symptoms	Low-dose vaginal estrogen, vaginal DHEA, ospemifene, or nonhormone local options depending on history	A local problem does not automatically need a systemic drug
Treatment while still perimenopausal	You heard tibolone was “all-in-one”	A clinician-chosen perimenopause regimen rather than tibolone	Current tibolone labels place natural-menopause use after the 12-month mark

Disqualifying honestly: if your only symptoms are vaginal dryness, burning, urinary discomfort, or pain with sex, close the systemic-drug comparison. A local treatment discussion is more direct. Start with our vaginal estrogen guide rather than solving a local problem with a whole-body drug.

Before you compare providers, choose your row
Write down the one outcome from the table that matters most to you. That single choice—route, bleeding, hot-flash control, libido, bone, or local symptoms—will keep a provider’s marketing from deciding for you.

What are women actually trying to get from tibolone?

Bottom line: The search is usually not about pharmacology. It is about exhaustion: one tablet instead of several products, less bleeding, sleep without sweats, sex without pain, desire that feels like yours again, or a clinician who will stop dismissing the problem. Those are separate needs, and they do not all point to the same drug.

Here is the decision-friction map we use instead of unverified testimonials:

The sentence underneath the search	The decision it should trigger
“I cannot keep track of a patch and a capsule.”	Compare one-product FDA-approved combinations, not just tibolone versus separate products
“The bleeding is making me quit.”	Check timing, regimen, adherence, and whether the bleeding needs investigation before switching
“I want my libido back.”	Separate pain, dryness, sleep, desire, and HSDD; do not use an androgenic-sounding metabolite as a diagnosis
“I am scared of clots.”	Compare oral and transdermal routes explicitly
“I moved to the U.S. and nobody knows this drug.”	Build a transition plan around the reason you took tibolone, not a one-for-one replacement that does not exist
“I only need help with painful sex.”	Leave the systemic comparison and evaluate local GSM treatment

We deliberately did not publish patient efficacy quotes here. A dramatic “it changed my life” statement about a drug an American reader cannot obtain as an FDA-approved product would add emotion and subtract judgment. The emotions are real. The testimonial is not the evidence.

What should you do if you take tibolone and are moving to the U.S.?

Bottom line: A foreign tibolone prescription cannot simply become an FDA-approved U.S. refill because no approved U.S. product exists. Plan a clinician-led transition before your supply runs low. Foreign visitors may fall under a limited FDA personal-importation framework with documentation, but U.S. residents should not assume that overseas shipment or continued importation will be allowed.

Of everyone reading this page, you have the most urgent practical problem and the least useful generic advice. So here it is directly.

What will not create a durable U.S. plan

Asking a U.S. pharmacy to order an FDA-approved tibolone product that does not exist
Assuming a foreign prescription automatically transfers
Depending on recurring overseas shipments
Accepting a compounded product without written disclosure of the legal basis, source, testing, and non-FDA-approved status
Waiting until the last tablet to find a prescriber

The FDA says a foreign national visiting the United States may, in some circumstances, bring or receive up to a 90-day supply with appropriate documentation. That is not the same as a U.S. resident having a permanent import right. Immigration status, length of stay, drug status, documentation, quantity, and border discretion all matter.

A practical transition sequence

1. Start while you still have a margin. Eight to twelve weeks is a practical planning window, not a medical rule. It gives you time to find a clinician, transfer records, and handle an insurance or pharmacy delay.
2. Write down exactly what tibolone solved. Hot flashes, sleep, bleeding, vaginal symptoms, sexual pain, desire, mood, or bone concerns. The U.S. replacement path should target the reason—not imitate the tablet.
3. Bring the product record. Brand, strength, country, start date, prescriber, last natural period or surgical-menopause date, bleeding pattern, adverse effects, and any relevant bone or cancer history.
4. Do not stop or improvise a switch on your own. Symptoms can recur, and the route, dose, and endometrial-protection plan need to be chosen together.
5. Expect a route conversation. The answer may be a patch plus progesterone, a combination product, a local vaginal treatment, a nonhormone option, or more than one intervention. There is no exact American tibolone swap.

Copy or print this tibolone transition checklist

[ ] Current brand name, strength, and country of supply
[ ] Date started and number of tablets remaining
[ ] Date of last natural menstrual bleed, or date/type of menopause-related surgery
[ ] Whether you have a uterus and ovaries
[ ] Symptoms tibolone improved, did not improve, or worsened
[ ] Bleeding or spotting pattern, including when it began
[ ] Previous hormone regimens and why you stopped them
[ ] Breast, uterine, clot, stroke, heart, liver, migraine, and bone history
[ ] Current medicines and supplements
[ ] Preferred route: patch, gel, spray, tablet, vaginal treatment, or no preference
[ ] Insurance or cash-pay limit
[ ] The question you need answered before you leave the appointment

Use your browser’s print command or copy the checklist into your patient portal message. You cannot hand a clinician a vague memory of “the European HRT pill.” You can hand them this.

Where is tibolone currently available?

Bottom line: Official sources confirm current tibolone products in Canada, the United Kingdom, and Australia. The United States has no FDA-approved product. Availability elsewhere changes by national authorization, marketing status, brand, and supply, so a broad “available across most of the world” sentence is less useful than checking the country’s live medicines registry.

Country	Verified status in August 2026	Product and key rule
United States	No FDA-approved tibolone product	No ordinary approved prescription route; import and compounding questions are not substitutes for approval
Canada	Approved and marketed	Tibella 2.5 mg; short-term vasomotor-symptom treatment more than one year after menopause; current monograph limits use to women with intact uteri and says reassess after six months
United Kingdom	Prescription-only product listed	Livial 2.5 mg; one tablet daily; natural-menopause start at least 12 months after the last bleed; do not add a separate progestogen
Australia	Prescription-only Schedule 4 product listed	Livial 2.5 mg; for postmenopausal women more than one year after menopause
Another country	Not assumed	Search the national regulator’s current product database and the manufacturer’s local product information before treating a brand listing as proof of current supply

The timing rule catches people out. In the UK, natural-menopause treatment starts at least 12 months after the last natural bleed; surgical menopause has a separate rule. In Canada, Tibella is indicated more than one year after menopause and only for women with intact uteri. A forum answer from another country can therefore be clinically and legally wrong for you even when the molecule is the same.

Which U.S. online care path fits if tibolone is unavailable?

Bottom line: For FDA-approved estradiol-based care online, Midi Health and Sesame use different payment models. Midi offers menopause care in all 50 states, bills many commercial PPO plans, and charges $250 for the first self-pay visit and $150 for follow-ups. Sesame’s menopause program is a $59-per-month cash-pay subscription; medication costs are separate.

The current payment models are easy to confuse: Sesame’s menopause service is a subscription, and Midi treats Medicare and Medicaid differently.

Provider-stated versus what we verified

Decision factor	Midi Health	Sesame menopause subscription
Best fit	Ongoing menopause-focused care, especially when a commercial PPO plan is in-network or route choice matters	Predictable cash-pay subscription with ongoing video care and messaging
Current published price	First self-pay visit $250; follow-up $150	$59/month
Membership	No membership required	Monthly subscription
Insurance	In-network with most PPO plans; copay, deductible, and coinsurance vary	Does not bill health insurance for the subscription
Medicare / Medicaid	Medicare is out of network; beneficiaries may self-pay but cannot submit related claims. Medicaid and Medi-Cal patients are not accepted.	Cash-pay service; verify eligibility and any state-specific restrictions during enrollment
Medication cost	Not established by the visit price; confirm drug and pharmacy cost separately	Not included in the subscription; varies by insurance status and pharmacy
Labs	Clinician may recommend targeted labs; cost depends on the order and coverage	Listed basic labs are included if ordered, with direct-pay exceptions in NY, NJ, RI, and ND and different lab networks in several states
State access	Menopause care advertised in all 50 states	Provider availability and service eligibility depend on location
Cancellation / refund friction	No recurring membership to cancel	Self-cancel before the next billing cycle; prior months are nonrefundable. The first month is refundable only if canceled at least three hours before the initial visit and the visit has not occurred.
Medication lane for this page	Ask specifically for FDA-approved options and verify the dispensed product	Page lists FDA-approved estradiol and combination options; confirm exactly what the clinician prescribes

The honest limitation of the higher-touch path

Midi is not the cheap cash-pay answer. The first self-pay visit is $250 and follow-ups are $150. Medicare beneficiaries can use it only as self-pay and cannot submit related claims; Medicaid and Medi-Cal patients are not accepted.

If those facts make Midi a bad fit, stop trying to force it. A clinician who takes your government coverage, or a lower-cost cash model, is the better path. We would rather lose the click than waste your afternoon.

The pivot is equally real: Midi has no membership, is available for menopause care in all 50 states, bills many commercial PPO plans, and discusses multiple FDA-approved routes. For a woman whose problem is finding ongoing menopause-focused care and choosing between a patch, gel, oral product, and local therapy, that model may justify the higher self-pay price.

The honest limitation of the lower monthly price

Sesame’s $59 is the care subscription, not the total treatment cost. Medication costs are separate. Labs are included only when ordered and state exceptions apply. You must cancel before the next billing cycle to avoid another charge, and the first month is not refundable after the initial visit occurs.

The pivot: the price is published, the program includes video visits as needed and unlimited messaging, and the page lists estradiol and estrogen-progestin treatment options. That can fit a woman who wants predictable cash-pay ongoing access and understands that the prescription and pharmacy bill are separate decisions.

A visit with either service is an evaluation, not a promise that a clinician will prescribe the route or product you request.

FDA-approved and compounded are not interchangeable. Before paying for any hormone medication, ask the clinician and dispensing pharmacy to state whether the exact product is FDA-approved or compounded, identify the manufacturer or compounding pharmacy, and explain why that route fits your situation. This page recommends the FDA-approved lane for a U.S. alternative to tibolone; it does not use a compounded product as a substitute for a drug that lacks FDA approval.

Does one of those care models sound like your situation?
Match your symptoms, route preference, insurance or cash-pay situation, state, and safety flags before choosing. The result shows a best-fit care path, two backups, and when online care is not the right starting point.
→ Match your situation to the right care model

How did The HRT Index verify this page?

Bottom line: Regulatory claims were checked against current government or official product records, pooled clinical numbers against the systematic review, and trial-specific figures against the original studies. Where the public evidence did not support certainty—especially U.S. compounding and importation—we narrowed the claim instead of filling the gap with confidence.

What we actually verified

Claim	Primary or authoritative check	Last checked
No FDA-approved U.S. tibolone product	Sponsor announcement of the June 2006 Not Approvable Letter and withdrawal; current absence of an approved product	August 28, 2026
503A nomination status	FDA nominated-bulk-substances document updated May 14, 2026; tibolone absent from Categories 1–3	August 28, 2026
Personal importation policy	FDA’s current personal-importation page	August 28, 2026
UK dose, timing, bleeding, contraindications, endometrial and breast warnings	Current Livial 2.5 mg Summary of Product Characteristics	August 28, 2026
Canadian indication and intact-uterus restriction	Current Tibella product monograph and Health Canada approval records	August 28, 2026
Australian marketed product	Australian Commission on Safety and Quality in Health Care medicine finder	August 28, 2026
Hot-flash comparison	Cochrane review of 46 trials and 19,976 women	August 28, 2026
LISA bleeding and sexual-function figures	Original randomized-trial publications	August 28, 2026
Stroke, fracture, and breast-cancer-survivor outcomes	LIFT and LIBERATE original trial reports	August 28, 2026
Endometrial-risk comparison	Million Women Study and UK primary-care cohort	August 28, 2026
Midi and Sesame commercial facts	Current provider pricing, insurance, service, lab, and cancellation pages	August 28, 2026

What we could not verify—and did not pretend to

Whether tibolone currently has an applicable USP or National Formulary monograph that would independently satisfy the relevant 503A bulk-substance condition
A patient-specific 503B outsourcing-facility route
Whether an individual import shipment would receive FDA enforcement discretion
Your pharmacy price, formulary, prior-authorization rule, deductible, copay, or coinsurance
Current marketed supply in every country where tibolone has historically been licensed
Whether a particular clinician will prescribe a requested product before completing an evaluation

The review standard

This page follows The HRT Index Verification Standard: we read every published price, separate FDA-approved from compounded, verify state availability and insurance, and re-check on a fixed schedule—top providers monthly, the full roster quarterly.

We evaluate providers on five pillars, always in this order: clinical legitimacy, care quality, medication fit, price transparency, access. We do not turn those pillars into a numeric score, because one number would hide the exact tradeoffs this page is built to expose.

A timestamp moves only when the claims are rechecked. Editing a sentence does not count as verification.

Affiliate disclosure: The HRT Index may earn a commission from some providers linked through this site. That does not change the price you pay. Commercial relationships do not convert compounded medication into FDA-approved medication, erase a coverage exclusion, or decide which care model fits you.

Frequently asked questions

Is tibolone available in the United States?

No FDA-approved tibolone product is available in the United States. We found no routine, transparent, verifiable U.S. prescribing route. Personal importation is generally illegal and any FDA enforcement discretion is case-specific rather than guaranteed.

Is tibolone the same as estradiol?

No. Estradiol products deliver estradiol itself. Tibolone is a synthetic steroid rapidly converted into metabolites with estrogenic, progestogenic, and androgenic activity. They are not dose-equivalent or interchangeable.

Why is tibolone not FDA approved?

Organon announced that the FDA issued a Not Approvable Letter in June 2006 and that it would withdraw the application. We found no public FDA review explaining the reason. LIFT had been stopped for stroke four months earlier, but timing is not proof of causation.

Can a compounding pharmacy make tibolone in the U.S.?

We did not find a routine verified pathway. Tibolone is absent from the FDA’s May 14, 2026 503A nominated-bulk categories and is not a component of an FDA-approved U.S. drug. Because an applicable USP/NF monograph is a separate statutory route and we could not verify its status publicly, we will not claim that every conceivable patient-specific compound is categorically unlawful. Any compound would still be non-FDA-approved.

Can I legally order Livial or tibolone from another country?

Importing an unapproved prescription drug is generally illegal for U.S. residents. The FDA may consider enforcement discretion in limited, documented circumstances, but that is case-specific and not a right. Do not depend on recurring overseas shipments for continuity of care.

Does tibolone cause weight gain?

Weight increase is listed as a common adverse reaction in the current Livial information. A small nonrandomized study found a less favorable BMI change with tibolone than transdermal estradiol, but its design cannot prove tibolone caused the difference. Track your baseline and discuss a meaningful change with your prescriber.

Does tibolone help libido more than estradiol?

Not clearly. In LISA, satisfying sexual events rose from three to four per 28 days in both groups. Tibolone’s questionnaire advantage appeared only in the per-protocol analysis, not the intention-to-treat analysis.

Do you need progesterone with tibolone?

The Livial label says a separate progestogen should not be added. That does not erase endometrial risk: current UK labeling and observational evidence report an increased rate of diagnosed endometrial cancer with tibolone. Report bleeding that persists after six months, starts later, or continues after stopping.

Is tibolone safe after breast cancer?

No. Tibolone is contraindicated after breast cancer. LIBERATE found a 40% higher recurrence hazard in women treated for breast cancer within the previous five years, and the trial stopped early. A systemic hormone decision after breast cancer belongs with the oncology team.

Is tibolone safe over 60?

The UK regulator says the risks begin to outweigh the benefits beyond about 60 because of stroke. That is not an automatic birthday cutoff, but it is a strong reason for individual arterial-risk assessment and a serious comparison with non-oral estradiol or nonhormone options.

Can I take tibolone if I am still having periods?

Not under the standard natural-menopause timing in the current UK and Canadian information. The UK label says to begin at least 12 months after the last natural bleed; Canada indicates Tibella more than one year after menopause. Surgical menopause follows separate rules.

What is the closest U.S. equivalent to tibolone?

There is no direct equivalent. Duavee is the closest practical “one product without a separate progestogen” concept, but it contains conjugated estrogens and bazedoxifene—not estradiol or tibolone. Bijuva, Activella, and CombiPatch combine estradiol with endometrial protection in one FDA-approved product.

How do I switch from tibolone to estradiol?

Do not design the switch yourself. Bring the brand, dose, treatment duration, bleeding pattern, uterus status, symptoms, and relevant risk history to a U.S. prescriber before your supply runs out. Expect the decision to focus on route and treatment goal rather than a milligram-for-milligram swap.

Does tibolone cause less bleeding than estradiol HRT?

It caused much less bleeding than the estradiol/norethisterone patch used in LISA: 16% versus 56% in weeks 1–12, and 12% versus 51% in weeks 13–24. That result does not apply to every estradiol regimen, and persistent or late bleeding still needs evaluation.

Is a patch safer than tibolone for blood clots?

Transdermal estradiol has a route advantage for venous-thromboembolism risk: NICE says VTE risk is not increased with transdermal HRT, while it is increased with oral HRT. Tibolone is oral only. Your broader cardiovascular, breast, and uterine history still matters.

Still not sure which HRT program is right for you? Take our free 90-second matching quiz.

Sources

Provider facts verified August 28, 2026

Put this comparison in context

Review the verified U.S. tibolone availability guide, compare the best online HRT providers, or start with the Find My HRT Path tool before choosing a medication route.

Keep reading: